Cited by 2,020Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisOccupational and environmental lung diseasesPulmonary Hypertension Research and Treatments

The DOI matches its Crossref record; 141 of the 143 references it cites were found in a registry or an index.

Idiopathic pulmonary fibrosis

Richeldi, Luca, Collard, Harold R, Jones, Mark G·2017·The Lancet

DOI 10.1016/s0140-6736(17)30866-8

Open this paper in CoChat — free account

Abstract

Idiopathic pulmonary fibrosis is a prototype of chronic, progressive, and fibrotic lung disease. Healthy tissue is replaced by altered extracellular matrix and alveolar architecture is destroyed, which leads to decreased lung compliance, disrupted gas exchange, and ultimately respiratory failure and death. In less than a decade, understanding of the pathogenesis and management of this disease has been transformed, and two disease-modifying therapies have been approved, worldwide. In this Seminar, we summarise the presentation, pathophysiology, diagnosis, and treatment options available for patients with idiopathic pulmonary fibrosis. This disease has improved understanding of the mechanisms of lung fibrosis, and offers hope that similar approaches will transform the management of patients with other progressive fibrotic lung diseases.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(17)30866-8

Cites

141 of 141 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cancer Incidence in Five Continents
Doll, R., Muir, C. S., & Waterhouse, J. A. H. (1970) · Springer eBooks · doi:10.1007/978-3-642-85851-2 · Cited by 8,485
An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citation
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Self-citation
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
Travis, W. D., Costabel, U., Hansell, D. M., King, T. E., Lynch, D. A., Nicholson, A. G., Ryerson, C. J., Ryu, J. H., Selman, M., Wells, A. U., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201308-1483st · Cited by 4,378
Self-citation
American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.2.ats01 · Cited by 4,196
Fleischner Society: Glossary of Terms for Thoracic Imaging
Hansell, D. M., Bankier, A. A., MacMahon, H., McLoud, T. C., Müller, N. L., & Rémy, J. (2008) · Radiology · doi:10.1148/radiol.2462070712 · Cited by 4,189
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,651
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis: An Update of the 2011 Clinical Practice Guideline
Raghu, G., Rochwerg, B., Zhang, Y., Garcia, C. A. C., Azuma, A., Behr, J., Brozek, J. L., Collard, H. R., Cunningham, W., Homma, S., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201506-1063st · Cited by 1,916
Self-citation

Show all 143 references

Research works printed but not linked: 1

2000, Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS), Am J Respir Crit Care Med, 161, 646, 10.1164/ajrccm.161.2.ats3-00 · DOI

Sorted by citations

Items 301–400 of 1,003

In Vivo Models for the Study of Fibrosis
Padmanabhan, J., Maan, Z. N., Kwon, S. H., Kosaraju, R. S., Bonham, C. A., & Gurtner, G. C. (2019) · Advances in Wound Care · doi:10.1089/wound.2018.0909 · Cited by 46
Potential Role of Cellular Senescence in Asthma
Wang, Z.-N., Su, R., Yang, B.-Y., Yang, K., Yang, L., Yan, Y., & Chen, Z. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00059 · Cited by 48
Asiaticoside might attenuate bleomycin‐induced pulmonary fibrosis by activating cAMP and Rap1 signalling pathway assisted by A2AR
Luo, J., Zhang, T., Zhu, C., Sun, J., Zhu, W., Ai, W., Huang, X., & Wang, X. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15505 · Cited by 46
Vitamin D suppresses bleomycin-induced pulmonary fibrosis by targeting the local renin–angiotensin system in the lung
Chang, J., Nie, H., Ge, X., Du, J., Liu, W., Li, X., Sun, Y., Wei, X., Xun, Z., & Li, Y. C. (2021) · Scientific Reports · doi:10.1038/s41598-021-96152-7 · Cited by 48
Reticulocalbin 3 Deficiency in Alveolar Epithelium Exacerbated Bleomycin-induced Pulmonary Fibrosis
Jin, J., Shi, X., Li, Y., Zhang, Q., Guo, Y. A., Li, C., Tan, P., Fang, Q., Ma, Y., & Ma, R. Z. (2018) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2017-0347oc · Cited by 46
Fibroblasts—Warriors at the Intersection of Wound Healing and Disrepair
Roman, J. (2023) · Biomolecules · doi:10.3390/biom13060945 · Cited by 44
Treatment of acute lung injury and early- and late-stage pulmonary fibrosis with combination emulsion siRNA polyplexes
Wang, Y., Ding, L., Li, Z., Chen, G., Sun, M., & Oupický, D. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.10.030 · Cited by 47
Prolonged Scar-in-a-Jar: an in vitro screening tool for anti-fibrotic therapies using biomarkers of extracellular matrix synthesis
Rønnow, S. R., Dabbagh, R. Q., Genovese, F., Nanthakumar, C. B., Barrett, V., Good, R. B., Brockbank, S., Cruwys, S., Jessen, H., Sørensen, G. L., et al. (2020) · Respiratory Research · doi:10.1186/s12931-020-01369-1 · Cited by 47
Autophagy in pulmonary fibrosis: friend or foe?
Hill, C. N., & Wang, Y. (2021) · Genes & Diseases · doi:10.1016/j.gendis.2021.09.008 · Cited by 46
Coomassie brilliant blue G-250 dye attenuates bleomycin-induced lung fibrosis by regulating the NF-κB and NLRP3 crosstalk: A novel approach for filling an unmet medical need
Zohny, M. H., Cavalu, S. D., Youssef, M. E., Kaddah, M. M. Y., Mourad, A. A. E., Gaafar, A. G. A., El-Ahwany, E. G., Amin, N. A., Arakeep, H. M., Shata, A., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112723 · Cited by 45
Elongation factor-2 kinase acts downstream of p38 MAPK to regulate proliferation, apoptosis and autophagy in human lung fibroblasts
Wang, Y., Huang, G., Wang, Z., Qin, H., Mo, B., & Wang, C. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2018.01.019 · Cited by 45
Notch3 Deficiency Attenuates Pulmonary Fibrosis and Impedes Lung-Function Decline
Vera, L., García‐Olloqui, P., Petri, E., Viñado, A. C., Valera, P. S., Blasco‐Iturri, Z., Calvo, I. A., Cenzano, I., Ruppert, C., Zulueta, J. J., et al. (2021) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2020-0516oc · Cited by 44
Diagnosis of Idiopathic Pulmonary Fibrosis in High-Resolution Computed Tomography Scans Using a Combination of Handcrafted Radiomics and Deep Learning
Refaee, T., Salahuddin, Z., Frix, A.-N., Yan, C., Wu, G., Woodruff, H. C., Gietema, H. A., Meunier, P., Louis, R. E., Guiot, J., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.915243 · Cited by 46
Role of Ferroptosis in Regulating the Epithelial–Mesenchymal Transition in Pulmonary Fibrosis
Ling, H., Xiao, H., Luo, T. L., Lin, H., & Deng, J. (2023) · Biomedicines · doi:10.3390/biomedicines11010163 · Cited by 42
What Do We Need to Know About Rising Rates of Idiopathic Pulmonary Fibrosis? A Narrative Review and Update
Pergolizzi, J. V., LeQuang, J. A., Varrassi, M., Breve, F., Magnusson, P., & Varrassi, G. (2023) · Advances in Therapy · doi:10.1007/s12325-022-02395-9 · Cited by 46
Macrophage-derived GPNMB trapped by fibrotic extracellular matrix promotes pulmonary fibrosis
Wang, J., Zhang, X., Min, L., Yuan, M., Yin, J., Luo, W. F., Wang, S., Cai, Y., Jiang, W., & Chao, J. (2023) · Communications Biology · doi:10.1038/s42003-022-04333-5 · Cited by 46
Gender differences at presentation of idiopathic pulmonary fibrosis in Sweden
Kalafatis, D., Gao, J., Pesonen, I., Carlson, L., Sköld, C. M., & Ferrara, G. (2019) · BMC Pulmonary Medicine · doi:10.1186/s12890-019-0994-4 · Cited by 44
CT/NIRF dual-modal imaging tracking and therapeutic efficacy of transplanted mesenchymal stem cells labeled with Au nanoparticles in silica-induced pulmonary fibrosis
Huang, J., Huang, J., Ning, X., Luo, W., Chen, M., Wang, Z., Zhang, W., Zhang, Z., & Chao, J. (2020) · Journal of Materials Chemistry B · doi:10.1039/c9tb02652e · Cited by 44
G-CSF Inhibits Pulmonary Fibrosis by Promoting BMSC Homing to the Lungs via SDF-1/CXCR4 Chemotaxis
Zhao, F., Cheng, T., Yang, L., Huang, Y., Li, C., Han, J., Li, X., Fang, L.-J., Feng, D., Tang, Y., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-65580-2 · Cited by 44
Paracrine SPARC signaling dysregulates alveolar epithelial barrier integrity and function in lung fibrosis
Conforti, F., Ridley, R. A., Brereton, C. J., Alzetani, A., Johnson, B., Marshall, B. G., Fletcher, S., Ottensmeier, C. H. H., Richeldi, L., Skipp, P. J. S., et al. (2020) · Cell Death Discovery · doi:10.1038/s41420-020-0289-9 · Cited by 43
Self-citation
Repurposing of histone deacetylase inhibitors: A promising strategy to combat pulmonary fibrosis promoted by TGF-β signalling in COVID-19 survivors
Krishna Murthy, P., Sivashanmugam, K., Kandasamy, M., Rajasekaran, S., & Ravikumar, V. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118883 · Cited by 41
Relationship between illness perception, fear of progression and quality of life in interstitial lung disease patients: A cross‐sectional study
Liu, Q., Qin, T., Hu, B. X., Zhao, Y., & Zhu, X. (2021) · Journal of Clinical Nursing · doi:10.1111/jocn.15852 · Cited by 44
Aryl hydrocarbon receptor signals attenuate lung fibrosis in the bleomycin-induced mouse model for pulmonary fibrosis through increase of regulatory T cells
Takei, H., Yasuoka, H., Yoshimoto, K., & Takeuchi, T. (2020) · Arthritis Research & Therapy · doi:10.1186/s13075-020-2112-7 · Cited by 49
Snail-mediated partial epithelial mesenchymal transition augments the differentiation of local lung myofibroblast
Wang, Y., Li, S., Zhao, J., Li, Q., Xu, C., Wu, H., Zhu, Z., & Tian, L. (2020) · Chemosphere · doi:10.1016/j.chemosphere.2020.128870 · Cited by 43
Use of the patientMpower App With Home-Based Spirometry to Monitor the Symptoms and Impact of Fibrotic Lung Conditions: Longitudinal Observational Study
Edwards, C. C., Costello, E., Cassidy, N., Vick, B., & Russell, A. (2020) · JMIR mhealth and uhealth · doi:10.2196/16158 · Cited by 44
CircRNA_0026344 via exosomal miR-21 regulation of Smad7 is involved in aberrant cross-talk of epithelium-fibroblasts during cigarette smoke-induced pulmonary fibrosis
Bai, J., Jianjun, D., Han, Z., Cui, Y., He, R., Gu, Y., & Zhang, Q. (2021) · Toxicology Letters · doi:10.1016/j.toxlet.2021.04.017 · Cited by 43
Icariside Ⅱ attenuates bleomycin-induced pulmonary fibrosis by modulating macrophage polarization
Deng, L., Ouyang, B., Shi, H., Yang, F., Li, S., Xie, C. H., Du, W., Hu, L., Wei, Y., & Dong, J. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116810 · Cited by 43
Salvia miltiorrhiza Restrains Reactive Oxygen Species-Associated Pulmonary Fibrosis via Targeting Nrf2-Nox4 Redox Balance
Peng, L., An, L., Sun, N.-Y., Ma, Y., Zhang, X., Liu, W., Liu, B., Li, P., & Chen, J. (2019) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x19500575 · Cited by 42
pH‐Triggered Aggregation of Gold Nanoparticles for Enhanced Labeling and Long‐Term CT Imaging Tracking of Stem Cells in Pulmonary Fibrosis Treatment
Yu, C., Chen, Z., Li, X., Bao, H., Wang, Y., Zhang, B., Huang, J., & Zhang, Z. (2021) · Small · doi:10.1002/smll.202101861 · Cited by 43
Gasotransmitters: Potential Therapeutic Molecules of Fibrotic Diseases
Chen, Y., Yuan, S., Cao, Y., Kong, G., Jiang, F., Li, Y., Wang, Q., Tang, M., Zhang, Q., Wang, Q., et al. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/3206982 · Cited by 43
Functional Au nanoparticles for engineering and long-term CT imaging tracking of mesenchymal stem cells in idiopathic pulmonary fibrosis treatment
Bao, H., Cheng, S., Li, X., Li, Y., Yu, C., Huang, J., & Zhang, Z. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121731 · Cited by 43
The emerging roles of ferroptosis in organ fibrosis and its potential therapeutic effect
Huang, X., Song, Y., Wei, L., Guo, J., Xu, W., & Li, M. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109812 · Cited by 42
Tectorigenin: A Review of Its Sources, Pharmacology, Toxicity, and Pharmacokinetics
Rong, J., Fu, F., Han, C., Wu, Y., Xia, Q., & Du, D. (2023) · Molecules · doi:10.3390/molecules28155904 · Cited by 41
Nebulized milk exosomes loaded with siTGF-β1 ameliorate pulmonary fibrosis by inhibiting EMT pathway and enhancing collagen permeability
Qiu, C., Zhao, Z., Xu, C., Yuan, R., Ha, Y., Tu, Q., Zhang, H., Mu, Z., Xin, Q., Tian, Y., et al. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02721-z · Cited by 44
A Shared Pattern of β-Catenin Activation in Bronchopulmonary Dysplasia and Idiopathic Pulmonary Fibrosis
Sucre, J. M. S., Deutsch, G. H., Jetter, C. S., Ambalavanan, N., Benjamin, J. T., Gleaves, L. A., Millis, B. A., Young, L. R., Blackwell, T. S., Kropski, J. A., et al. (2018) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.12.004 · Cited by 41
Short- and long-term effects of pulmonary rehabilitation for idiopathic pulmonary fibrosis: a systematic review and meta-analysis
Cheng, L., Tan, B., Yin, Y., Wang, S., Jia, L., Warner, G., Jia, G., & Jiang, W. (2018) · Clinical Rehabilitation · doi:10.1177/0269215518779122 · Cited by 41
Discovery of (S)-3-(3-(3,5-Dimethyl-1H-pyrazol-1-yl)phenyl)-4-((R)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)butanoic Acid, a Nonpeptidic αvβ6 Integrin Inhibitor for the Inhaled Treatment of Idiopathic Pulmonary Fibrosis
Procopiou, P. A., Anderson, N. A., Barrett, J., Barrett, T. N., Crawford, M. H. J., Fallon, B. J., Hancock, A. P., Le, J., Lemma, S., Marshall, R. P., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00959 · Cited by 41
Pericyte-myofibroblast transition in the human lung
Yamaguchi, M., Hirai, S., Tanaka, Y., Sumi, T., Tada, M., Takahashi, H., Watanabe, A., & Sakuma, Y. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.05.091 · Cited by 41
Co-delivery of siPTPN13 and siNOX4 via (myo)fibroblast-targeting polymeric micelles for idiopathic pulmonary fibrosis therapy
Hou, J., Ji, Q., Ji, J., Ju, S., Xu, C., Yong, X., Xu, X., Muddassir, M., Chen, X., Xie, J., et al. (2021) · Theranostics · doi:10.7150/thno.54217 · Cited by 45
Tacrolimus ameliorates bleomycin-induced pulmonary fibrosis by inhibiting M2 macrophage polarization via JAK2/STAT3 signaling
Liu, B., Jiang, Q., Chen, R., Gao, S., Xia, Q., Zhu, J., Zhang, F., Shao, C., Liu, X., Li, X., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109424 · Cited by 41
Comparison of oral ibuprofen and indomethacin therapy for patent ductus arteriosus in preterm infants.
Fakhraee, S. H., Badiee, Z., Mojtahedzadeh, S., Kazemian, M., & Kelishadi, R. (2007) · PubMed · Cited by 39
Modeling diverse genetic subtypes of lung adenocarcinoma with a next-generation alveolar type 2 organoid platformPreprint
Naranjo, S., Cabana, C. M., LaFave, L. M., Romero, R., Shanahan, S.-L., Bhutkar, A. J., Westcott, P. M. K., Schenkel, J. M., Ghosh, A., Liao, L. Z., et al. (2022) · Genes & Development · doi:10.1101/gad.349659.122 · Cited by 42
Magnetic liposome as a dual-targeting delivery system for idiopathic pulmonary fibrosis treatment
Wang, X., Wang, Y., Xue, Z., Wan, W., Li, Y., Qin, H., Zhu, Y., Tian, F., & Yang, J. (2023) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2023.01.007 · Cited by 40
Beyond DNA sensing: expanding the role of cGAS/STING in immunity and diseases
Seok, J. K., Kim, M., Kang, H. C., Cho, Y., Lee, H. S., & Lee, J. Y. (2023) · Archives of Pharmacal Research · doi:10.1007/s12272-023-01452-3 · Cited by 45
Recent developments in dry powder inhalation (DPI) formulations for lung-targeted drug delivery
Yang, M.-S., Kang, J., Kim, D., & Park, C. (2023) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-023-00635-w · Cited by 41
ACSS3 regulates the metabolic homeostasis of epithelial cells and alleviates pulmonary fibrosis
Wang, L., Yuan, H., Li, W., Yan, P., Zhao, M., Li, Z., Zhao, H., Wang, S., Wan, R., Li, Y., et al. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166960 · Cited by 40
Downregulation of HMGB1 is required for the protective role of Nrf2 in EMT‐mediated PF
Qu, J., Zhang, Z., Zhang, P., Zheng, C., Zhou, W., Cui, W., Xu, L., & Gao, J. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27548 · Cited by 40
The novel inhibitor PRI-724 for Wnt/β-catenin/CBP signaling ameliorates bleomycin-induced pulmonary fibrosis in mice
Okazaki, H., Sato, S., Koyama, K., Morizumi, S., Abe, S., Azuma, M., Chen, Y., Goto, H., Aono, Y., Ogawa, H., et al. (2019) · Experimental Lung Research · doi:10.1080/01902148.2019.1638466 · Cited by 42
Vitamin D deficiency exacerbates bleomycin-induced pulmonary fibrosis partially through aggravating TGF-β/Smad2/3-mediated epithelial-mesenchymal transition
Li, S.-R., Tan, Z.-X., Chen, Y., Hu, B., Zhang, C., Wang, H., Zhao, H., & Xu, D. (2019) · Respiratory Research · doi:10.1186/s12931-019-1232-6 · Cited by 40
Therapeutic potential of plant-derived tannins in non-malignant respiratory diseases
Rajasekaran, S., Rajasekar, N., & Sivanantham, A. (2021) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2021.108632 · Cited by 40
Natural Product-Based Potential Therapeutic Interventions of Pulmonary Fibrosis
Hasan, M., Paul, N. C., Paul, S. K., Saikat, A. S. M., Akter, H., Mandal, M., & Lee, S. (2022) · Molecules · doi:10.3390/molecules27051481 · Cited by 42
Effects of Anthraquinones on Immune Responses and Inflammatory Diseases
Xin, D., Li, H., Zhou, S., Zhong, H., & Pu, W. (2022) · Molecules · doi:10.3390/molecules27123831 · Cited by 43
Biomarkers of cellular senescence in idiopathic pulmonary fibrosis
Aversa, Z., Atkinson, E. J., Carmona, E. M., White, T. A., Heeren, A. A., Jachim, S. K., Zhang, X., Cummings, S. R., Chiarella, S. E., LIMPER, A. H., et al. (2023) · Respiratory Research · doi:10.1186/s12931-023-02403-8 · Cited by 41
Liproxstatin-1 alleviates bleomycin-induced alveolar epithelial cells injury and mice pulmonary fibrosis via attenuating inflammation, reshaping redox equilibrium, and suppressing ROS/p53/α-SMA pathway
Tao, N., Li, K., Liu, J., Fan, G., & Sun, T. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.02.127 · Cited by 39
Protective effect of dimethyl itaconate against fibroblast–myofibroblast differentiation during pulmonary fibrosis by inhibiting TXNIP
Han, Y., Gu, X., Yang, C., Ji, H.-M., Lan, Y., Bi, Y., Si, R., Qu, J., Cheng, M.-H., & Gao, J. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30456 · Cited by 39
The molecular mechanisms underlying anti‐inflammatory effects of galangin in different diseases
Hassanein, E. H. M., El‐Maksoud, M. S. A., Ibrahim, I. M., Abd‐alhameed, E. K., Althagafy, H. S., Mohamed, N. M., & Ross, S. A. (2023) · Phytotherapy Research · doi:10.1002/ptr.7874 · Cited by 42
The role of natural products targeting macrophage polarization in sepsis-induced lung injury
Li, Y., Ai, S., Li, Y., Ye, W., Li, R., Xu, X., & Liu, Q. (2025) · Chinese Medicine · doi:10.1186/s13020-025-01067-4 · Cited by 40
Inhibition of lncRNA PFRL prevents pulmonary fibrosis by disrupting the miR-26a/smad2 loop
Jiang, H., Chen, Y., Yu, T., Zhao, X., Shan, H., Sun, J., Zhang, L., Li, X., Shan, H., & Liang, H. (2018) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00434.2017 · Cited by 39
Efficacy and safety of N‑acetylcysteine therapy for idiopathic pulmonary fibrosis: An updated systematic review and meta‑analysis
Fen, F., Zhang, J., Wang, Z., Wu, Q., & Zhou, X. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7579 · Cited by 39
Exploring the Ability of Electronic Nose Technology to Recognize Interstitial Lung Diseases (ILD) by Non-Invasive Breath Screening of Exhaled Volatile Compounds (VOC): A Pilot Study from the European IPF Registry (eurIPFreg) and Biobank
Krauss, E., Haberer, J., Maurer, O., Barreto, G., Drakopanagiotakis, F., Degen, M., Seeger, W., & Günther, A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101698 · Cited by 39
P2 Purinergic Signaling in the Distal Lung in Health and Disease
Wirsching, E., Fauler, M., Fois, G., & Frick, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144973 · Cited by 42
FOXL1 Regulates Lung Fibroblast Function Via Multiple Mechanisms
Miyashita, N., Horie, M., Suzuki, H. I., Saito, M., Mikami, Y., Okuda, K., Boucher, R. C., Suzukawa, M., Hebisawa, A., Saito, A., et al. (2020) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2019-0396oc · Cited by 39
Overcoming interferon (IFN)-γ resistance ameliorates transforming growth factor (TGF)-β-mediated lung fibroblast-to-myofibroblast transition and bleomycin-induced pulmonary fibrosis
Chang, C., Lin, C., Lee, C., Chuang, H., Shih, F.-C., Wan, S.-W., Tai, C., & Chen, C. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114356 · Cited by 40
Antifibrotic effect of Gancao Ganjiang decoction is mediated by PD-1 / TGF-β1 / IL-17A pathway in bleomycin-induced idiopathic pulmonary fibrosis
Wang, D., Gong, L., Li, Z., Chen, H., Xu, M., Rong, R., Zhang, Y., & Zhu, Q. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114522 · Cited by 39
Extracellular vesicles in idiopathic pulmonary fibrosis: pathogenesis and therapeutics
Fujita, Y. (2022) · Inflammation and Regeneration · doi:10.1186/s41232-022-00210-0 · Cited by 39
The pathogenesis of organ fibrosis: Focus on necroptosis
Hao, M., Han, X., Yao, Z., Zhang, H., Zhao, M., Peng, M., Wang, K., Shan, Q., Sang, X., Wu, X., et al. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15952 · Cited by 40
Phenotypic drug screening in a human fibrosis model identified a novel class of antifibrotic therapeutics
Gerckens, M., Schorpp, K., Pelizza, F., Wögrath, M., Reichau, K., Ma, H., Dworsky, A.-M., Sengupta, A., Stoleriu, M. G., Heinzelmann, K., et al. (2021) · Science Advances · doi:10.1126/sciadv.abb3673 · Cited by 41
Preparation and evaluation of pirfenidone loaded chitosan nanoparticles pulmonary delivery for idiopathic pulmonary fibrosis
Dudhat, K. R., & Patel, H. (2022) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-022-00419-3 · Cited by 42
Animal models of acute exacerbation of pulmonary fibrosis
Xu, Y., Zhang, M., Gu, H., Liu, M., Zhao, Y., Shi, Y., Wu, S., Jiang, C., Ye, X., Zhu, H., et al. (2023) · Respiratory Research · doi:10.1186/s12931-023-02595-z · Cited by 38
NMDA receptor activation inhibits the antifibrotic effect of BM-MSCs on bleomycin-induced pulmonary fibrosis
Li, X., Li, C., Tang, Y., Huang, Y., Cheng, Q., Huang, X., Zhao, F., Hao, C., Feng, D., Xu, J., et al. (2018) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00002.2018 · Cited by 38
Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis
Belhassen, M., Dalon, F., Nolin, M., & Van Ganse, E. (2021) · Respiratory Research · doi:10.1186/s12931-021-01714-y · Cited by 38
Recent advances in studies of 15-PGDH as a key enzyme for the degradation of prostaglandins
Sun, C., Zhou, Z., Yang, D. K., Chen, Z., Zhou, Y., Wen, W., Chen, F., Zheng, L., Peng, X., & Tang, C. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108176 · Cited by 44
Real‐Time Measurement of Cell Mechanics as a Clinically Relevant Readout of an In Vitro Lung Fibrosis Model Established on a Bioinspired Basement Membrane
Doryab, A., Taskin, M. B., Stahlhut, P., Gröll, J., & Schmid, O. (2022) · Advanced Materials · doi:10.1002/adma.202205083 · Cited by 42
TIMP-1 and its potential diagnostic and prognostic value in pulmonary diseases
Almuntashiri, S., Alhumaid, A., Zhu, Y., Han, Y., Dutta, S., Khilji, O., Zhang, D., & Wang, X. (2023) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2023.05.002 · Cited by 40
Inhaled nanoparticles for treating idiopathic pulmonary fibrosis by inhibiting honeycomb cyst and alveoli interstitium remodeling
Han, M., Ling, T., Huang, B., Li, X., Fang, Y., Qi, L., Duan, B., Yao, Y., He, Y., Xing, L., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.01.032 · Cited by 37
Insights from human genetic studies of lung and organ fibrosis
Garcia, C. K. (2018) · Journal of Clinical Investigation · doi:10.1172/jci93556 · Cited by 37
The Effects of Epigallocatechin Gallate (EGCG) on Pulmonary Fibroblasts of Idiopathic Pulmonary Fibrosis (IPF)—A Next-Generation Sequencing and Bioinformatic Approach
Tsai, M., Chang, W., Liao, S., Chang, K., Sheu, C., & Kuo, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081958 · Cited by 37
Diffuse smoking-related lung diseases: insights from a radiologic-pathologic correlation
Sousa, C., Junior, M. R. R., Carvalho, A., Viamonte, B., Cunha, R., Guimarães, S., Moura, C. S., Morais, A., & Pereira, J. M. (2019) · Insights into Imaging · doi:10.1186/s13244-019-0765-z · Cited by 40
Cell-specific expression of lung disease risk-related genes in the human small airway epithelium
Zuo, W.-L., Rostami, M. R., Shenoy, S. A., LeBlanc, M. G., Salit, J., Strulovici‐Barel, Y., O’Beirne, S. L., Kaner, R. J., Leopold, P. L., Mezey, J. G., et al. (2020) · Respiratory Research · doi:10.1186/s12931-020-01442-9 · Cited by 37
Indirubin alleviates bleomycin-induced pulmonary fibrosis in mice by suppressing fibroblast to myofibroblast differentiation
Wang, Q., Yu, J., Hu, Y., Chen, X., Zhang, L., Pan, T. S., Miao, K., Mou, Y., Xu, Y., Xiong, W., et al. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110715 · Cited by 37
The Roles of CCN1/CYR61 in Pulmonary Diseases
Zhu, Y., Almuntashiri, S., Han, Y., Wang, X., Somanath, P. R., & Zhang, D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217810 · Cited by 37
The Role of Interaction between Mitochondria and the Extracellular Matrix in the Development of Idiopathic Pulmonary Fibrosis
Siekacz, K., Piotrowski, W. J., Iwański, M. A., Górski, P., & Białas, A. J. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/9932442 · Cited by 40
Benzyl butyl phthalate (BBP) induces lung injury and fibrosis through neutrophil extracellular traps
Wang, W., Liu, Z., Zhang, Y., Wang, L., Meng, D., Li, X., Zhang, J., Wu, Y., Zhou, X., & Liu, G. (2022) · Environmental Pollution · doi:10.1016/j.envpol.2022.119743 · Cited by 37
Roles of exosomes and exosome-derived miRNAs in pulmonary fibrosis
Yang, Y., Huang, H., & Li, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.928933 · Cited by 38
Regulating the cell shift of endothelial cell-like myofibroblasts in pulmonary fibrosis
Wu, X., Zhang, D., Qiao, X., Zhang, L., Cai, X., Ji, J., Ma, J. A., Zhao, Y., Belperio, J. A., Boström, K. I., et al. (2023) · European Respiratory Journal · doi:10.1183/13993003.01799-2022 · Cited by 36
Traditional Chinese medicine inspired dual-drugs loaded inhalable nano-therapeutics alleviated idiopathic pulmonary fibrosis by targeting early inflammation and late fibrosis
Zheng, M., Liu, K., Li, L., Feng, C., & Wu, G. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02251-0 · Cited by 37
Glycolysis and beyond in glucose metabolism: exploring pulmonary fibrosis at the metabolic crossroads
Wang, Y., Wang, X., Du, C., Wang, Z., Wang, J., Zhou, N., Wang, B., Tan, K., Fan, Y., & Cao, P. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1379521 · Cited by 39
Sirt1 antisense long non-coding RNA attenuates pulmonary fibrosis through sirt1-mediated epithelial-mesenchymal transition
Qian, W., Cai, X., & Qian, Q. (2020) · Aging · doi:10.18632/aging.102882 · Cited by 36
A review for natural polysaccharides with anti-pulmonary fibrosis properties, which may benefit to patients infected by 2019-nCoV
Chen, R., Li, Y., Chen, J.-J., & Lu, C. (2020) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2020.116740 · Cited by 37
Automatic quantitative computed tomography measurement of longitudinal lung volume loss in interstitial lung diseases
Si-Mohamed, S. A., Nasser, M., Colevray, M., Nempont, O., Lartaud, P.-J., Vlachomitrou, A. S., Broussaud, T., Ahmad, K., Traclet, J., Cottin, V., et al. (2022) · European Radiology · doi:10.1007/s00330-021-08482-9 · Cited by 37
Role of Ferroptosis in Fibrotic Diseases
Zhou, J., Tan, Y., Wang, R., & Li, X. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s358470 · Cited by 36
Astaxanthin: A promising therapeutic agent for organ fibrosis
Li, K., Wang, W., & Xiao, W. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106657 · Cited by 37
Recapitulating essential pathophysiological characteristics in lung-on-a-chip for disease studies
Zhang, Y., Wang, X., Yang, Y. L., Yan, J., Xiong, Y., Wang, W., Lei, J., & Jiang, T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1093460 · Cited by 37
Natural plant resource flavonoids as potential therapeutic drugs for pulmonary fibrosis
Wang, M. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e19308 · Cited by 35
Decoding organ fibrosis: mechanistic insights and emerging therapeutic strategies
Chen, X., Zhang, J., Guo, L., Wu, C., Zhou, J., Xu, M., Mo, L., Li, Y., & He, J. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02532-0 · Cited by 40
Changing causes of death for patients with chronic respiratory disease in England, 2005-2015
Gayle, A., Axson, E. L., Bloom, C. I., Navaratnam, V. V., & Quint, J. K. (2019) · Thorax · doi:10.1136/thoraxjnl-2018-212514 · Cited by 35
Stemona alkaloids suppress the positive feedback loop between M2 polarization and fibroblast differentiation by inhibiting JAK2/STAT3 pathway in fibroblasts and CXCR4/PI3K/AKT1 pathway in macrophages
Ding, Q., Sun, J., Xie, W., Zhang, M., Zhang, C., & Xu, X. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.04.030 · Cited by 36
Galangin ameliorated pulmonary fibrosis in vivo and in vitro by regulating epithelial-mesenchymal transition
Wang, L., Liu, H., He, Q., Gan, C., Li, Y., Zhang, Q., Yao, Y., He, F., Ye, T., & Yin, W. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115663 · Cited by 35
Low let‐7d exosomes from pulmonary vascular endothelial cells drive lung pericyte fibrosis through the TGFβRI/FoxM1/Smad/β‐catenin pathway
Xie, H., Gao, Y., Zhang, Y., Jia, M., Peng, F., Meng, Q., & Wang, Y. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15989 · Cited by 35
Intestinal Fibrosis and Gut Microbiota: Clues From Other Organs
Zhan, S., Li, N., Liu, C., Mao, R., Wu, D., Li, T., Chen, M., Zhuang, X., & Zeng, Z. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.694967 · Cited by 35

Authors: Richeldi, L., Collard, H. R., & Jones, M. G.
Affiliations: Università Cattolica del Sacro Cuore (IT)
University of California, San Francisco (US)
National Institute for Health and Care Research (GB)
Corresponding author: Richeldi, Luca
ORCID: Richeldi, Luca
Collard, Harold R
Jones, Mark G
Venue: The Lancet
Publisher: Elsevier BV
Published: 2017-05
Volume: 389
Issue: 10082
Pages: 1941-1952
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(17)30866-8
OpenAlex: W2599075603
Cited by: 2,020
References: 143
Citations by year: 2026: 202 · 2025: 317 · 2024: 338 · 2023: 293 · 2022: 273 · 2021: 233 · 2020: 167 · 2019: 94 · 2018: 76 · 2017: 22
FWCI: 17.97
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
ePrints Soton (University of Southampton) (acceptedVersion)
Funders: National Institute for Health and Care Research (CL-2016-26-004)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
Keywords: idiopathic pulmonary fibrosis, pulmonary fibrosis, pathophysiology, extracellular matrix, alveolar architecture, disease-modifying therapy, diagnosis, treatment options, respiratory failure
MeSH terms: Humans, Idiopathic Pulmonary Fibrosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Idiopathic pulmonary fibrosis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks